Good morning, Broadsheet readers! Moms are at the forefront of advocating for tech accountability, fewer women in India are working despite the rising population, and abortion pill startups Hey Jane and Choix contend with the legal battle over mifepristone. Take care this Tuesday!
- A hard pill. Two startups providing easy-access abortion pills are considering how they may need to alter their business models after Friday’s dueling rulings on the Food and Drug Administration’s approval of mifepristone, a drug commonly used in medical abortions.
On Friday, Judge Matthew J. Kacsmaryk of the northern Texas U.S. district invalidated FDA approval of mifepristone, siding with anti-abortion groups and doctors who claimed in a November lawsuit that the FDA didn't do enough research to prove mifepristone is safe and effective. (He stayed his decision for seven days to allow for appeals; mifepristone remains on the market.) The FDA has disputed the argument, saying it has continuously reviewed the drug since granting initial approval more than 20 years ago.
